Free tool
FAERS Monitor: Nulytely
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019797 or its brand name (Nulytely, Polyethylene Glycol 3350, Potassium Chloride, Sodium Bicarbonate, Sodium Chloride). Reports on generic versions are filed under their own applications.
Reports
248
Serious
151
61% of reports
Hospitalization
79
Death reported
30
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- vomiting34
- nausea28
- drug ineffective14
- fatigue14
- pneumonia14
- chronic kidney disease13
- abdominal distension12
- renal failure12
- asthenia11
- constipation11
- diarrhoea11
- dyspnoea11
- headache11
- acute kidney injury10
- death10
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 7 |
| 2012 | 2 |
| 2013 | 17 |
| 2014 | 5 |
| 2015 | 16 |
| 2016 | 19 |
| 2017 | 24 |
| 2018 | 29 |
| 2019 | 23 |
| 2020 | 24 |
| 2021 | 7 |
| 2022 | 25 |
| 2023 | 9 |
| 2024 | 15 |
| 2025 | 16 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,911 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic kidney diseaseSignal | 13 | 14.5 | 8.5 | 151 |
| abdominal distensionSignal | 12 | 9.8 | 5.6 | 86 |
| renal failureSignal | 12 | 7.7 | 4.4 | 63 |
| vomitingSignal | 34 | 6.1 | 4.5 | 144 |
| acute kidney injurySignal | 10 | 5.5 | 3.0 | 33 |
| constipationSignal | 11 | 4.3 | 2.4 | 25 |
| pneumoniaSignal | 14 | 3.7 | 2.2 | 25 |
| nauseaSignal | 28 | 3.0 | 2.1 | 37 |
| astheniaSignal | 11 | 2.5 | 1.4 | 8 |
| dyspnoea | 11 | 1.6 | 0.9 | 2 |
| fatigue | 14 | 1.5 | 0.9 | 2 |
| headache | 11 | 1.5 | 0.8 | 1 |
| diarrhoea | 11 | 1.4 | 0.8 | 1 |
| death | 10 | 1.0 | 0.5 | 0 |
| drug ineffective | 14 | 0.9 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.